NDRG1 and triple-negative breast carcinoma: A recent study by Mao et al. demonstrated that the promoter region of the NDRG1 was bonded by YAP1 and NDRG1 could affect cell proliferation and chemotherapy sensitivity in triple-negative breast cancer [27].